Alan H. Bryce, MD

Articles

Dr. Bryce on the FDA Approval of Rucaparib in BRCA-Mutant mCRPC

May 20th 2020

Alan H. Bryce, MD, discusses the accelerated approval of rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy.

Dr. Bryce on Ongoing Research Regarding CDK12 Alterations in Prostate Cancer

January 30th 2020

Alan H. Bryce, MD, discusses ongoing research regarding CDK12 alterations in prostate cancer.

Dr. Bryce on Ongoing Research in Prostate Cancer

January 29th 2020

Alan H. Bryce, MD, assistant professor of medicine and medical director of the Genomic Oncology Clinic, Mayo Clinic, discusses ongoing research in prostate cancer.

Dr. Bryce on Next-Generation Radiopharmaceuticals in Prostate Cancer

January 17th 2020

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the use of next-generation radiopharmaceuticals in prostate cancer.

Dr. Bryce on Potential Biomarkers of Response to Immunotherapy in Prostate Cancer

November 20th 2019

Alan H. Bryce, MD, discusses potential biomarkers of response to immunotherapy in prostate cancer.

Dr. Bryce on Treatment Selection in Nonmetastatic Castration-Resistant Prostate Cancer

October 25th 2019

Alan H. Bryce, MD, discusses treatment selection in nonmetastatic castration-resistant prostate cancer.

Dr. Bryce on the Use of Abiraterone Versus Docetaxel in Patients With Prostate Cancer

February 28th 2018

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the importance of individualized approaches in the use of abiraterone (Zytiga) versus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Dr. Alan Bryce on Molecular Testing in Metastatic or High-Risk Stage III Melanoma

May 8th 2015

Alan H. Bryce, MD, medical oncologist, Mayo Clinic, discusses the need for molecular testing in patients with metastatic or high-risk stage III melanoma.